Abstract:Abstract Background The development of antibodies (inhibitors) to clotting factors compromises the treatment of people with Hemophilia A (HA) and B (HB), and results in ineffective clotting-factor therapy, higher risk of complications, and need for bypassing agents to achieve hemostatic control. Objectives To evaluate the association between presence of inhibitors and peri-operative hemostatic control, complications, and deviations from pre-surgery plans. Methods We conducted a retrospective study using data from the Indiana Hemophilia and Thrombosis Center (IHTC) surgical database (1998 - 2019). Association between specified outcomes and inhibitor status at surgery was assessed using generalized linear models while controlling for patient and procedural characteristics. Results A total of 1,492 surgeries were conducted in 539 patients with HA or HB, 4.8%(72/1492) of which were conducted in 20 (15 HA; 5HB) patients with inhibitors. Of the 72 surgeries involving inhibitors, 30 were high-titer, 10 low-titer and 32 with unreported inhibitor titers. Adjusting for patient's age, hemophilia diagnosis, surgery setting, and surgery type, the risk of achieving perioperative hemostasis was lower in surgeries involving inhibitors compared to non-inhibitor surgeries (65.6% vs 91.4%; aRR=0.78; 95% CI= 0.61-0.99; p=0.038). Complications including hemorrhage, fever, pain, thrombosis, and infections occurred more frequently in surgeries involving inhibitors (31.7% vs 14.6%; aRR= 1.67, 95% CI= 1.07 - 2.63; p=0.025). Deviation from pre-surgical plans, usually due to the development of complications including lack of effective hemostatic control, also occurred more frequently in surgeries involving inhibitors compared to those without inhibitors (70.8 vs 39.5%; aRR= 1.63, 95% CI= 1.33 - 2.01; p<0.001). Conclusion Procedures involving patients with inhibitors have increased risk of adverse perioperative outcomes compared to those without inhibitors. Key Words: Inhibitors, Hemophilia, Surgery, Perioperative outcomes, Database. Disclosures Iorio: McMaster University: Current Employment; Bayer (funding to the institution): Research Funding; BioMarin (funding to the institution): Research Funding; NovoNordisk (funding to the institution): Research Funding; Octapharma (funding to the institution): Research Funding; Pfizer (funding to the institution): Research Funding; Roche (funding to the institution): Research Funding; Sanofi (funding to the institution): Research Funding; Sobi (funding to the institution): Research Funding; Takeda (funding to the institution): Research Funding. Malec: CSL Behring: Consultancy; Genentech: Consultancy; HEMA Biologics: Consultancy; Pfizer: Consultancy; Sanofi: Consultancy, Research Funding; Takeda: Consultancy. Matino: Bayer: Membership on an entity's Board of Directors or advisory committees, Other: research grants and personal fees; Pfizer: Membership on an entity's Board of Directors or advisory committees, Other: research grants and personal fees; Novo Nordisk: Membership on an entity's Board of Directors or advisory committees, Other: research grants and personal fees; Sanofi: Membership on an entity's Board of Directors or advisory committees, Other: research grants and personal fees; Spark: Other: research grants; Octopharma: Membership on an entity's Board of Directors or advisory committees, Other: research grants and personal fees; Sobi: Membership on an entity's Board of Directors or advisory committees, Other: personal fees. Shapiro: Pfizer: Research Funding; Novartis: Research Funding; Sangamo: Other: Advisory board fees, Research Funding; Sigilon Therapeutics: Other: Advisory board fees, Research Funding; Bioverativ (a Sanofi company): Other: Advisory board fees, Research Funding; Daiichi Sankyo: Research Funding; Genentech: Other: Advisory board fees, Research Funding, Speakers Bureau; Glover Blood Therapeutics: Research Funding; Kedrion Biopharma: Research Funding; Novo Nordisk: Other: Advisory board fees, Research Funding, Speakers Bureau; Prometric BioTherapeutics: Research Funding; Octapharma: Research Funding; OPKO: Research Funding; Agios: Research Funding; BioMarin: Research Funding; Takeda: Research Funding.

Perioperative Management for Port Catheter Procedures in Pediatric Patients with Severe Hemophilia and Inhibitors

Perioperative Outcomes Associated with Inhibitor Status in Patients with Hemophilia - a Retrospective Cohort Study

Peri-operative Anticoagulation Strategies, Bleeding and Thrombotic Complications in Pediatric Patients Undergoing Intervention for Congenital Portosystemic Shunts

Retrospective study on management of the perioperative period in 41 cases of hemophilic children with surgical diseases

Risk of bleeding and inhibitor development after circumcision of previously untreated or minimally treated severe hemophilia A children

Invasive procedures in patients with haemophilia: Review of low‐dose protocols and experience with extended half‐life FVIII and FIX concentrates and non‐replacement therapies

Haemophilia in the first years of life

Regular prophylaxis with activated prothrombin complex concentrates in pediatric hemophilia

Complications of central venous access devices in paediatric haemophilia patients

Haemostatic efficacy of single-dose factor administration in neonates with severe haemophilia undergoing circumcision

Recombinant porcine factor VIII in patients with congenital haemophilia A with inhibitors undergoing surgery: Phase 3, single‐arm, open‐label study

Management and monitoring of anticoagulation for children undergoing cardiopulmonary bypass in cardiac surgery

Current Perioperative Anticoagulation Practices in Children with Prosthetic Mechanical Heart Valves

Perioperative considerations in the paediatric patient with congenital and acquired coagulopathy

Clots and bleeds: the outcomes of percutaneous coronary intervention in hemophilia patients with acute coronary syndrome

A Mid-Term, Large, and Successful Series at a Single Center

Two-incision laparoscopic appendectomy for a severe hemophilia A child patient with coagulation factor VII deficiency: Case report and review of literature

Surveillance of Infectious Complications Associated with Central Venous Access Devices in Children with Haemophilia

Utility of Blood Cultures and Empiric Antibiotics in Febrile Pediatric Hemophilia Patients With Central Venous Access Devices

Barriers to primary prophylaxis in haemophilic children: the issue of the venous access

Modern Treatment of Valvulopathies in Patients with Congenital Hemophilia